Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.21037/atm-20-4354
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2021
- Creator
- DOI
-
10.18154/RWTH-2021-09141
- URN
-
urn:nbn:de:101:1-2021100803251924642151
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tacke, Frank
- Weiskirchen, Ralf
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2021
Other Objects (12)
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease